Genomic test to rule out obstructive CAD may reduce need for more invasive diagnostics

©2014 Mary Ann Liebert, Inc., publishers

Nearly $7 billion is spent each year in the U.S. on diagnostic testing of the estimated three million people with symptoms of obstructive coronary artery disease (CAD). A new blood test that detects specific genes activated in individuals with obstructive CAD could exclude the diagnosis without the need for imaging studies or more invasive tests, reducing health care costs, as described in an article in Population Health Management, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

Louis Hochheiser (St. John's Medical Center, Jackson, WY), Jessie Juusola and Mark Monane (CardioDx, Palo Alto, CA), and Joseph Ladapo (New York University School of Medicine, NY), use a decision analysis model to compare the cost-effectiveness of "usual care" for obstructive CAD diagnosis with a strategy that includes "gene expression score (GES)-directed care." They present the results and potential value of this new diagnostic approach in the article "Economic Utility of a Blood-Based Genomic Test for the Assessment of Patients with Symptoms Suggestive of Obstructive Coronary Artery Disease".

"Work like this is vital to our understanding as we move from a world of volume to value," says Editor-in-Chief David B. Nash, MD, MBA, Dean and Dr. Raymond C. and Doris N. Grandon Professor, Jefferson School of Population Health, Philadelphia, PA.

More information: The article is available free on the Population Health Management website at http://www.liebertpub.com/pop.

add to favorites email to friend print save as pdf

Related Stories

Undiagnosed diabetes takes economic toll

May 07, 2009

Approximately 6.3 million adults—or one fourth of the people in the U.S. with diabetes mellitus—are unaware they have the disease, and this undiagnosed population accounts for an estimated $18 billion in health care costs ...

Recommended for you

Hopes dashed for an agent to prevent reperfusion injury

48 minutes ago

The administration of an experimental agent known as TRO40303 to patients who have had a heart attack, with the hope of preventing tissue damage when impaired blood flow is corrected (reperfusion), was disappointingly ineffective ...

User comments